Homepage Top Section2

The new combined formulation will be delivered using a breath-actuated nebuliser. Currently, AeroRx is said to be engaged in the development of the first nebulised LABA/LAMA combination solution

The latest announcement is expected to be beneficial for nearly 1,500 people aged 12 years and above with melanoma. This drug is said to be the first NICE-recommended

A PARP inhibitor, Lynparza is the first targeted treatment, which is designed to inhibit DNA damage response (DDR) in cells/tumours which harbour deficiency in homologous recombination repair (HRR),

Forxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is administered orally once every day. It has shown efficacy in preventing and delaying cardiorenal disease, while protecting the

Ultomiris is a long-acting C5 complement inhibitor that provides immediate, complete and sustained complement inhibition. It is indicated for adult gMG patients, who are anti-acetylcholine receptor (AChR) antibody-positive,

This study was undertaken in ~184 subjects, who were randomised 1:1 and received either a booster dose of the vaccine or a placebo, ~six months following the primary

Under the two-year sponsored research alliance, the companies will work to identify new drug candidates that enable inhibition of two proteins, Bax and Bak. These proteins are integral

Orion Biotechnology Canada is a drug discovery company targeting earlier undruggable GPCRs. A biotech firm, Peptilogics is into engineering peptide therapeutics by bringing together computation and biology to

These therapies will be developed using Ryvu’s stimulator of interferon genes (STING) technology. The deal expands Exelixis’ biotherapeutics portfolio by combining its tumour-specific targeting approaches with the Ryvu’s